RaDaR® ST

Use

Studies in solid tumors across multiple cancer types have consistently demonstrated that detection of circulating tumor DNA (ctDNA) for molecular residual disease (MRD) detection after surgery or systemic therapy is associated with a markedly increased risk of disease relapse in the absence of additional treatment. Conversely, patients in whom ctDNA is not detected post-curative therapy exhibit a substantially lower risk of recurrence, reflecting minimal or absent residual disease burden and constitutes one of the strongest indicators of favorable prognosis in multi-cancer settings. Additionally, ctDNA detection can precede conventional imaging findings by several months, providing an early indicator of recurrence risk and enabling closer surveillance or therapeutic intervention.